Código QR (código de barras bidimensional)

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study

Introduction: Deficiency of the dihydropyrimidine dehydrogenase enzyme can result in capecitabine-related toxicity due to genetic alterations in the DPYD gene, leading to complete or partial DPD deficiency and poor or intermediate metabolizer phenotypes. The distribution of DPYD variants varies acro...

ver descrição completa

Na minha lista:
Principais autores: Hemavathi Baskarane, Mohit Kumar Divakar, Akhil P. Santhosh, Kriti Pallavi, Vishakha Hooda, Vamsi Krishna Yenamandra, Saran Kumar, Vrajesh Shetty, Jahnavi Banotra, Ishaan Gupta, Shilpi Minocha, Pranay Tanwar, Atul Sharma, Payal Vasudeva, Akash Kumar, R. Chethan, Sameer Bakhshi, Atul Batra
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2026-02-01
coleção:Frontiers in Pharmacology
Assuntos:
cancer genomics
capecitabine toxicity
DPYD gene polymorphism
D-TORCH trial
pharmacogenomics (PGx)
pharmacogentics
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2026.1732128/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados